Erlotinib and bevacizumab have synergistic activity against melanoma. [electronic resource]
Producer: 20090803Description: 3495-502 p. digitalISSN:- 1078-0432
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Cell Line
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Drug Synergism
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Female
- Humans
- Immunoblotting
- Immunohistochemistry
- Ki-67 Antigen -- analysis
- Lung Neoplasms -- drug therapy
- Melanoma, Experimental -- drug therapy
- Mice
- Mice, SCID
- Platelet Endothelial Cell Adhesion Molecule-1 -- analysis
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinazolines -- administration & dosage
- Signal Transduction -- drug effects
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.